AMLX (Amylyx Pharmaceuticals) Marketable Securities: $50.63 Mil (As of Mar. 2026)


AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $17.77
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Marketable Securities?

Amylyx Pharmaceuticals AMLX -3.29% 33 Marketable Securities is $50.63 Mil as of Mar. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Amylyx Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $50.63 Mil.

Amylyx Pharmaceuticals's annual Marketable Securities declined from Dec. 2023 ($201.16 Mil) to Dec. 2024 ($99.11 Mil) and declined from Dec. 2024 ($99.11 Mil) to Dec. 2025 ($90.33 Mil).

Amylyx Pharmaceuticals  (NAS:AMLX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Amylyx Pharmaceuticals Marketable Securities Related Terms

Amylyx Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals Marketable Securities Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 45.93 284.42 201.16 99.11 90.33

Amylyx Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.30 122.74 118.81 90.33 50.63
AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $50.63 Mil mean?
Amylyx Pharmaceuticals (AMLX) has a Marketable Securities of $50.63 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Amylyx Pharmaceuticals and its competitors.
Is Amylyx Pharmaceuticals' Marketable Securities too high?
Amylyx Pharmaceuticals' current Marketable Securities is $50.63 Mil. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Marketable Securities compare to ANIP and TRLV?
Amylyx Pharmaceuticals' Marketable Securities of $50.63 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Amylyx Pharmaceuticals and its competitors. Amylyx Pharmaceuticals's current Marketable Securities is $50.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Marketable Securities of $50.63 Mil. The current Marketable Securities is $50.63 Mil. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Marketable Securities is $50.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.77
Price